Previous 10 | Next 10 |
home / stock / hkmpf / hkmpf news
2023-05-06 05:25:00 ET Summary Hikma Pharmaceuticals is a FTSE 250 generic drug manufacturer that was founded in the Middle East in 1978. The company has many attractive features, including a long track record of progressive dividend growth, so I added it to my dividend portfolio ...
2023-03-29 06:05:32 ET Shanghai Junshi Biosciences ( OTCPK:SHJBF ) is collaborating with Rxilient Biotech to develop and sell cancer drug toripalimab through a joint venture, Excellmab, in nine Southeast Asian nations. Under the agreement, Rxilient will subscribe ...
The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q4 earnings call. For further details see: Hikma Pharmaceuticals PLC 2022 Q4 - Results - Earnings Call Presentation
Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 A.M. ET Company Participants Susan Ringdal - EVP, Strategic Planning and Global Affairs Said Darwazah - Chief Executive Officer Brian Hoffmann - President of Generics Riad Mis...
Hikma Pharmaceuticals press release ( OTCPK:HKMPF ): FY GAAP EPS of $1.81. Revenue of $2.52B (-1.2% Y/Y). 2023 Outlook: Injectables revenue growth in the range of 7% to 9%, with core operating margin in the range of 36% to 37% Branded revenue growth in the mid to high-sing...
Hikma Pharmaceuticals Plc. (HKMPF) 2022 Interim Results August 04, 2022 05:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference Call Participants Presentation Said Darwazah Hello everyo...
The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q2 earnings call. For further details see: Hikma Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation
Hikma Pharmaceuticals press release ( OTCPK:HKMPF ): 1H GAAP EPS of $76.20. Revenue of $1.21B (flat Y/Y) misses by $10M . Outlook for full year 2022: Injectables – we continue to expect revenue growth to be in the mid to high-single digits and core operating...
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals Canada NewsWire LONDON , April 29, 2022 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary ...
Update: Opiant Pharmaceuticals (NASDAQ:OPNT) has advised readers to disregard the news release issued via PR Newswire on Thursday about the purported licensing deal to market the company’s opioid overdose therapy OPNT003 in the EU and U.K. “This release contains incorrect inform...
News, Short Squeeze, Breakout and More Instantly...
Hikma Pharmaceuticals Plc Company Name:
HKMPF Stock Symbol:
OTCMKTS Market:
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals Canada NewsWire LONDON , April 29, 2022 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary ...
Hikma resumes launch of generic Advair Diskus® PR Newswire LONDON , April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of ...
LONDON , Sept. 3, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Nevada finding that Hikma's gen...